Novartis: Cardiovascular Diseases trials
The registry lists 32 Cardiovascular Diseases studies with Novartis as lead sponsor. 4 are open to participants now and 13 have results posted.
Phase 2 7Phase 3 16Phase 4 4No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabRecruitingNCT07543731
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in RussiaRecruitingNCT06858332
- Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaRecruitingNCT06597019Phase 3
- Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruitingNCT06597006Phase 3
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyCompletedNCT05305664Phase 3Results posted
- Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With HypercholesterolemiaCompletedNCT05192941Phase 4Results posted
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsCompletedNCT03066804Phase 3Results posted
- Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular DiseaseTerminatedNCT01562041Phase 2Results posted
- Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01090310Phase 3Results posted
- Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT PatientsCompletedNCT00995930Phase 2Results posted
- Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic HypertensionCompletedNCT00931710Phase 4Results posted
- LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection FractionCompletedNCT00887588Phase 2Results posted
- Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate HypertensionCompletedNCT00867490Phase 3Results posted
- Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment WithdrawalCompletedNCT00865020Phase 4Results posted
- Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe HypertensionCompletedNCT00841672Phase 3Results posted
- Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During ExerciseCompletedNCT00819767Phase 2Results posted
- Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)TerminatedNCT00549757Phase 3Results posted
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Active, not recruitingNCT07517263Phase 3
- A Study of DII235 in Adults With Elevated Lipoprotein(a)Active, not recruitingNCT07235046Phase 2
- Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United StatesCompletedNCT07214857
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDActive, not recruitingNCT06813911Phase 3
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVDCompletedNCT06267560Phase 3
- In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular DiseaseCompletedNCT05974345
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)TerminatedNCT05900141Phase 3
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Active, not recruitingNCT05739383Phase 3
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDCompletedNCT04023552Phase 3
- Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)CompletedNCT03887520Not applicable
- Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)CompletedNCT01546532Phase 2
- Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart FailureCompletedNCT01543854Phase 2
- Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart FailureCompletedNCT00894868Phase 4
- Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)CompletedNCT00079586Phase 3
- Angiomax in Patients With HIT/HITTS Type II Undergoing CPBCompletedNCT00079508Phase 3